Trials / Conditions / Obstructive Hypertrophic Cardiomyopathy

Obstructive Hypertrophic Cardiomyopathy

23 registered clinical trials studyying Obstructive Hypertrophic Cardiomyopathy — 7 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	A Phase III Trial of HRS-1893 in Patients With Obstructive Hypertrophic Cardiomyopathy NCT07021976	Shandong Suncadia Medicine Co., Ltd.	Phase 3
Active Not Recruiting	A Study to Learn More About How Well Aficamten Works in Japanese Participants With Symptomatic Obstructive Hyp NCT07023341	Bayer	Phase 3
Not Yet Recruiting	Efficacy of Mavacamten Combined With Radiofrequency Ablation in Patients With Symptomatic Obstructive Hypertro NCT06856265	Shanghai Chest Hospital	N/A
Active Not Recruiting	A Trial of HRS-1893 in Patients With Obstructive Hypertrophic Cardiomyopathy NCT06516068	Shandong Suncadia Medicine Co., Ltd.	Phase 2
Not Yet Recruiting	Feasibility Study of the DragonFire for Hypertrophic Obstructive Cardiomyopathy NCT06368037	Hangzhou Valgen Medtech Co., Ltd	N/A
Recruiting	A Study to Assess the Safety of Mavacamten in Korean Patients With Symptomatic Obstructive Hypertrophic Cardio NCT06146660	Bristol-Myers Squibb	—
Recruiting	Real-world Patient Reported Outcomes Among Patients Treated With Camzyos NCT06551129	Bristol-Myers Squibb	—
Completed	Effect of Verapamil Tablets on the Pharmacokinetic of HRS-1893 Tablets in Healthy Subjects NCT06354556	Shandong Suncadia Medicine Co., Ltd.	Phase 1
Unknown	Percutaneous Endocardial Septal Radiofrequency Ablation in Obstructive Hypertrophic Cardiomyopathy NCT06224621	China National Center for Cardiovascular Diseases	N/A
Completed	An Open-Label Study of Aficamten for Chinese Patients With Symptomatic oHCM NCT06116968	Corxel Pharmaceuticals	Phase 3
Recruiting	Effect of Mavacamten Treatment on Coronary Flow Reserve in oHCM NCT06023186	Michael Ayers	—
Completed	A Trial of HRS-1893 in Healthy Volunteers and Patients With Obstructive Hypertrophic Cardiomyopathy NCT05879523	Shandong Suncadia Medicine Co., Ltd.	Phase 1
Unknown	Feasibility Study of the DragonFire for Hypertrophic Obstructive Cardiomyopathy NCT06211595	Hangzhou Valgen Medtech Co., Ltd	N/A
Recruiting	A Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudina NCT05489705	Bristol-Myers Squibb	—
Completed	A Study to Evaluate the Efficacy and Safety of Mavacamten in Chinese Adults With Symptomatic Obstructive HCM NCT05174416	LianBio LLC	Phase 3
Completed	Myocardial Bridging in Obstructive Hypertrophic Cardiomyopathy NCT06598995	Chinese Academy of Medical Sciences, Fuwai Hospital	—
Completed	Safety, Tolerability and Pharmacokinetics Study of CK-3773274 NCT04783766	Corxel Pharmaceuticals	Phase 1
Completed	Patients' Long-Term Survival of Obstructive Hypertrophic Cardiomyopathy (HCM) NCT04603521	National Heart, Lung, and Blood Institute (NHLBI)	—
Completed	Use of Cryoenergy to Faciltate Myectomy in Hypertrophic Obstructive Cardiomyopathy: Comparison With the Classi NCT05726799	Michele De Bonis	—
Completed	A Long-Term Safety Extension Study of Mavacamten in Adults Who Have Completed MAVERICK-HCM or EXPLORER-HCM NCT03723655	Bristol-Myers Squibb	Phase 2 / Phase 3
Unknown	Permanent Pacing for Drug-refractory Symptomatic Patients With Obstructive Hypertrophic Cardiomyopathy. NCT05771987	Istituto Auxologico Italiano	N/A
Completed	Clinical Study to Evaluate Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic Cardiomyop NCT03470545	MyoKardia, Inc.	Phase 3
Completed	Effects of Continous Positive Airway Pressure (CPAP) in Hypertrophic Cardiomyopathy NCT01631006	University of Sao Paulo	N/A